Hans-Peter Vornlocher serves as a scientific advisor to City Therapeutics. He is senior advisor to Axolabs, the world leading CRO in the area of oligonucleotide therapeutics, a company Dr. Vornlocher co-founded in 2011. 

Under his scientific leadership, Axolabs supported numerous clients from pharma, biotech and academics in the preclinical and clinical development of oligonucleotide therapeutics. Until March of 2024, Dr. Vornlocher served as CSO for the Axolabs business unit and from 2012 to 2022 he was managing director research of Axolabs Kulmbach. Prior to that, Dr. Vornlocher acted as managing director for the Roche Center of Excellence for RNA Therapeutics in Kulmbach. As head of development at Ribopharma AG (2001 to 2003) and VP research at Alnylam (2003 to 2007), Dr. Vornlocher directed and published ground-breaking research in the area of RNAi therapeutics. 

Dr. Vornlocher has coauthored more than 60 peer reviewed papers and book chapters and is inventor on more than 50 patents and patent applications. He obtained a Ph.D. in biochemistry from the University of Bayreuth and conducted post-doctoral research at UC Davis, the Institute of Molecular Biology and Tumor Research of the University Marburg and the Max-Planck-Institute for Biophysical Chemistry in Göttingen with a focus on RNA translation and splicing.